Blog - Page 3 of 8

June 28, 2019May 31, 2019

Relative Efficacy Ketamine : Does the Formulation and Delivery Matter with Respect to Efficacy, Tolerability and Safety?

In March of 2019, the US FDA approved intranasal esketamine for treatment-resistant depression (TRD). Conceptually, this is an extraordinary event from the point of view of drug development in psychiatry insofar as this is the first time the FDA has approved an antidepressant medicine that was developed on the basis of an a priori diseases model (i.e. glutamatergic dysregulation relevant to the pathogenesis of mood disorders).

May 31, 2019June 21, 2019

Can We Predict Who will Respond to Ketamine/Esketamine in TRD?

The heterogeneity of treatment response in MDD has provided a compelling rationale for identifying predictors of response/tolerability (and non-response/intolerability) amongst individuals assigned to a given treatment. The need to identify predictors of response is even greater when the treatment options being considered are more costly, require more resources for administration (e.g. specialized clinics), and/or may be associated with greater safety/tolerability concerns.

February 21, 2019May 31, 2019

Esketamine (Spravato): What You Need To Know About Breakthrough The Nasal Spray

There’s tons of excitement in psychiatry after the US Food and Drug Administration advisory committee recently backed esketamine (Spravato), an intranasal form of ketamine for treatment-resistant depression. This is an exciting and hopeful advancement because there hasn’t been a different pharmacologic depression treatment target approved by the agency in decades (Think: Prozac’s arrival in 1986). Like any new drug, the excitement and hope surrounding esketamine (Spravato) needs to be weighed by risks and benefits. Here are a few things you need to know about esketamine (Spravato).

January 30, 2019May 31, 2019

What To Consider When Screening A Ketamine and Esketamine (Spravato) Clinic in Philadelphia

Ketamine Clinics are Popping Up Everywhere - Here's How to Screen Them. Ketamine is one of the most exciting treatments to emerge for mood disorders in decades.

January 23, 2019May 31, 2019

Rapid Relief From Depression: COPE Provides Innovative Options Treatment For St. Louis

Feelings of sadness, anxiety, loss of interest, and hopelessness can accumulate and become crippling.

COPE supported centers are pleased to provide a blog for patients and family members of patients that provides more information on ketamine treatments and mental illness.

Relative Efficacy Ketamine : Does the Formulation and Delivery Matter with Respect to Efficacy, Tolerability and Safety?

Can We Predict Who will Respond to Ketamine/Esketamine in TRD?

Esketamine (Spravato): What You Need To Know About Breakthrough The Nasal Spray

What To Consider When Screening A Ketamine and Esketamine (Spravato) Clinic in Philadelphia

Rapid Relief From Depression: COPE Provides Innovative Options Treatment For St. Louis

SUBSCRIBE

TOPICS

RECENT POSTS